116 related articles for article (PubMed ID: 17552551)
41. [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia].
Francz M
Magy Onkol; 2008 Mar; 52(1):35-40. PubMed ID: 18403295
[TBL] [Abstract][Full Text] [Related]
42. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform.
Pan S; Rush J; Peskind ER; Galasko D; Chung K; Quinn J; Jankovic J; Leverenz JB; Zabetian C; Pan C; Wang Y; Oh JH; Gao J; Zhang J; Montine T; Zhang J
J Proteome Res; 2008 Feb; 7(2):720-30. PubMed ID: 18186601
[TBL] [Abstract][Full Text] [Related]
43. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways.
Sun S; Lee NP; Poon RT; Fan ST; He QY; Lau GK; Luk JM
Liver Int; 2007 Oct; 27(8):1021-38. PubMed ID: 17845530
[TBL] [Abstract][Full Text] [Related]
44. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.
Wei YS; Zheng YH; Liang WB; Zhang JZ; Yang ZH; Lv ML; Jia J; Zhang L
Cancer; 2008 Feb; 112(3):544-51. PubMed ID: 18085639
[TBL] [Abstract][Full Text] [Related]
45. Protein arrays for biomarker discovery.
Reid JD; Parker CE; Borchers CH
Curr Opin Mol Ther; 2007 Jun; 9(3):216-21. PubMed ID: 17608019
[TBL] [Abstract][Full Text] [Related]
46. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
Zhang PJ; Gao HG; Pasha TL; Litzky L; Livolsi VA
Int J Gynecol Pathol; 2009 Jan; 28(1):10-8. PubMed ID: 19047914
[TBL] [Abstract][Full Text] [Related]
47. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
48. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer.
Zhao Z; Xiao Y; Elson P; Tan H; Plummer SJ; Berk M; Aung PP; Lavery IC; Achkar JP; Li L; Casey G; Xu Y
J Clin Oncol; 2007 Jul; 25(19):2696-701. PubMed ID: 17602074
[TBL] [Abstract][Full Text] [Related]
49. Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.
Chaker S; Kashat L; Voisin S; Kaur J; Kak I; MacMillan C; Ozcelik H; Siu KW; Ralhan R; Walfish PG
Proteomics; 2013 Mar; 13(5):771-87. PubMed ID: 23319340
[TBL] [Abstract][Full Text] [Related]
50. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
[TBL] [Abstract][Full Text] [Related]
51. Images in pathology. Signet ring cells in an endometrial biopsy: tumor or not tumor? That is the question.
Kuhn E; Manoni S; De Anda J
Int J Surg Pathol; 2006 Jul; 14(3):227. PubMed ID: 16959708
[No Abstract] [Full Text] [Related]
52. Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis.
Fata CR; Seeley EH; Desouki MM; Du L; Gwin K; Hanley KZ; Hecht JL; Jarboe EA; Liang SX; Parkash V; Quick CM; Zheng W; Shyr Y; Caprioli RM; Fadare O
Hum Pathol; 2015 Oct; 46(10):1427-36. PubMed ID: 26243671
[TBL] [Abstract][Full Text] [Related]
53. [Applications of DNA chip technology and protein mass spectrometry in the studies of reproduction and endocrinology].
Han CS
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):361-3. PubMed ID: 16831353
[No Abstract] [Full Text] [Related]
54. Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples.
Martinez-Garcia E; Lesur A; Devis L; Campos A; Cabrera S; van Oostrum J; Matias-Guiu X; Gil-Moreno A; Reventos J; Colas E; Domon B
Oncotarget; 2016 Aug; 7(33):53102-53115. PubMed ID: 27447978
[TBL] [Abstract][Full Text] [Related]
55. Assessing the statistical validity of proteomics based biomarkers.
Smit S; van Breemen MJ; Hoefsloot HC; Smilde AK; Aerts JM; de Koster CG
Anal Chim Acta; 2007 Jun; 592(2):210-7. PubMed ID: 17512828
[TBL] [Abstract][Full Text] [Related]
56. A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.
Pallares J; Santacana M; Puente S; Lopez S; Yeramian A; Eritja N; Sorolla A; Llobet D; Dolcet X; Matias-Guiu X
Anal Quant Cytol Histol; 2009 Aug; 31(4):217-26. PubMed ID: 19736869
[TBL] [Abstract][Full Text] [Related]
57. [Morphological disintegration of biological fluids and tissues and the imbalance of macro- and microelements].
Protasova OV; Maksimova IA; Botvin MA; Zakharova OV; Doletskaia DV
Fiziol Cheloveka; 2007; 33(2):104-9. PubMed ID: 17486996
[No Abstract] [Full Text] [Related]
58. Importance of communication between producers and consumers of publicly available experimental data.
Liotta LA; Lowenthal M; Mehta A; Conrads TP; Veenstra TD; Fishman DA; Petricoin EF
J Natl Cancer Inst; 2005 Feb; 97(4):310-4. PubMed ID: 15713967
[TBL] [Abstract][Full Text] [Related]
59. RAB8A a new biomarker for endometrial cancer?
Bie Y; Zhang Z
World J Surg Oncol; 2014 Dec; 12():371. PubMed ID: 25477298
[TBL] [Abstract][Full Text] [Related]
60. Identification and evaluation of a panel of serum biomarkers for predicting response to thalidomide in multiple myeloma patients.
Xiong Q; Ge F
Expert Rev Proteomics; 2011 Aug; 8(4):439-42. PubMed ID: 21819299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
